Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
- Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
- Iomab-B now has orphan designation in the US and EU
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.